Phaeton Research

Phaeton Research is a clinical-stage biopharmaceutical company specializing in the development of oral small-molecule therapies for rare diseases. The company's primary focus is the bradykinin B2 receptor, a key mediator in the pathology of Hereditary Angioedema (HAE). Its lead asset, deucrictibant (formerly PHA-022121), is a potent and selective B2 receptor antagonist currently being evaluated in late-stage clinical trials for both on-demand and prophylactic treatment of HAE attacks. Phaeton Research operates as a key research entity within Pharvaris, leveraging its expertise in the contact activation pathway to expand its pipeline into other bradykinin-mediated indications.